Retatrutide peptide results from clinical trials show substantial weight loss, but the drug is not FDA-approved. Here's what the data actually says.
Retatrutide peptide results from clinical trials show average weight loss of roughly 24% over 48 weeks at the highest dose tested — the largest reduction reported for any weight-loss drug candidate in a phase 2 study. Retatrutide is an investigational triple-agonist drug that targets GIP, GLP-1, and glucagon receptors at once, and it is not FDA-approved for any use in the United States. The numbers below come from controlled human trials, not from online seller claims.
Retatrutide Clinical Trial Results at a Glance
The most-cited data come from a phase 2 trial of 338 adults with obesity or overweight, published in the New England Journal of Medicine in 2023. Participants received weekly injections of retatrutide or placebo for 48 weeks. Weight loss was dose-dependent and was still increasing when the study ended.
| Weekly dose | Average weight change at 48 weeks |
|---|---|
| Placebo | About −2% |
| 1 mg | About −9% |
| 4 mg | About −17% |
| 8 mg | About −23% |
| 12 mg | About −24% |
Two patterns stand out in these results. First, the effect kept growing across the full 48 weeks rather than leveling off. Second, the gap between 8 mg and 12 mg was small, which suggests the dose-response curve flattens at the top end.
Retatrutide Results in People With Type 2 Diabetes
A separate phase 2 trial tested retatrutide in adults with type 2 diabetes. In that study, A1c fell by up to about 2 percentage points, and participants lost up to roughly 17% of body weight at 24 weeks on the highest dose.
People with diabetes usually lose less weight on GLP-1-based drugs than people without diabetes, so those numbers stand out. Blood sugar improvements appeared early, often within the first 12 weeks of treatment.
How Retatrutide Works and Why Results Vary
Retatrutide is a single peptide molecule that activates three receptors: GIP, GLP-1, and glucagon. GLP-1 and GIP reduce appetite and slow stomach emptying, while glucagon receptor activity appears to raise energy expenditure.
What shapes an individual result
- Dose: Higher weekly doses produced more weight loss in every trial arm.
- Time on treatment: Most participants were still losing weight at week 48.
- Baseline weight: People starting at higher weights tended to lose more total pounds.
- Adherence: Missed doses and early discontinuation lower total results.
Anyone asking what is the retatrutide peptide should understand that it is an injectable prescription-style drug in development, not a supplement, and there is no approved dosing schedule for home use.
Side Effects Reported in Retatrutide Trials
Gastrointestinal side effects were the most common and were generally mild to moderate. They included nausea, diarrhea, vomiting, and constipation, and they were most frequent during dose escalation.
- Nausea, sometimes with vomiting
- Small heart rate increases at higher doses
- Injection-site reactions
- Treatment discontinuation due to side effects in a minority of participants
Retatrutide is not FDA-approved for human use, so every safety signal comes from trials rather than long-term post-marketing data. People with a history of pancreatitis, gallbladder disease, or medullary thyroid cancer should talk with a clinician before considering any GLP-1-based drug.
Why Retatrutide Peptide Sold Online Is Not the Same Drug
Search interest in retatrutide has created a gray market of research-chemical vendors selling lyophilized powder labeled retatrutide peptide. These products are not approved, are not made under FDA oversight, and are often mislabeled or underdosed.
Because the powder has to be mixed before use, retatrutide peptide reconstitution introduces dosing errors that are easy to make and hard to catch. A small measurement mistake can deliver several times the intended dose.
People often read peptide partners retatrutide reviews, compare vendor listings, and hunt for third-party lab testing before ordering anything. No review thread replaces pharmaceutical-grade manufacturing and medical supervision.
Forum threads also lump retatrutide in with unrelated compounds. Searches for mots c peptide weight loss results and dsip peptide results reflect curiosity about peptides that work through entirely different pathways — MOTS-c is studied for metabolic health, and DSIP is studied for sleep. Neither is a GLP-1 drug.
What Retatrutide Results Mean for You
Retatrutide has produced the strongest weight-loss numbers of any investigational obesity drug in phase 2 testing so far. The phase 3 TRIUMPH program is ongoing, and approval, if it happens, is unlikely before 2026 at the earliest.
If you are interested in retatrutide, the safest path is a clinical trial or waiting for regulatory approval. In the meantime, a healthcare professional can help you weigh approved options and monitor side effects.
Frequently Asked Questions
What results did retatrutide show in clinical trials?
In a phase 2 trial, adults with obesity lost an average of about 24% of body weight after 48 weeks on the highest dose of 12 mg weekly, compared with about 2% on placebo. Lower doses produced smaller but still substantial losses of roughly 9% to 23%. Phase 3 trials are still running, so final numbers may differ.
Is retatrutide FDA-approved?
No. Retatrutide is an investigational drug and is not approved by the FDA for weight loss or any other indication. Approval, if it comes, would follow completion of the phase 3 TRIUMPH trials. Until then, it is legally available only through clinical trials.
Can you buy retatrutide peptide online?
Products labeled retatrutide peptide are sold by research-chemical vendors, but they are not FDA-approved, not intended for human use, and often lack verified purity or accurate dosing. Buying from these sources carries real risk of contamination, wrong dosing, and unknown side effects. Clinical trial enrollment and approved alternatives are the safer routes.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.